Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 87

1.

Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project.

Beau-Faller M, Pencreach E, Leduc C, Blons H, Merlio JP, Bringuier PP, de Fraipont F, Escande F, Lemoine A, Ouafik L, Denis M, Hofman P, Lacave R, Melaabi S, Langlais A, Missy P, Morin F, Moro-Sibilot D, Barlesi F, Cadranel J; French Cooperative Thoracic Intergroup (IFCT).

Lung Cancer. 2020 Feb;140:19-26. doi: 10.1016/j.lungcan.2019.10.013. Epub 2019 Nov 15.

PMID:
31841714
2.

Challenges in Assessing MYC Rearrangement in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg-Type.

Menguy S, Laharanne E, Prochazkova-Carlotti M, Gros A, Vergier B, Parrens M, Beylot-Barry M, Pham-Ledard A, Merlio JP.

Am J Surg Pathol. 2019 Nov 22. doi: 10.1097/PAS.0000000000001412. [Epub ahead of print] No abstract available.

PMID:
31764222
3.

The Need for a Consensus Next-generation Sequencing Panel for Mature Lymphoid Malignancies.

Sujobert P, Le Bris Y, de Leval L, Gros A, Merlio JP, Pastoret C, Huet S, Sarkozy C, Davi F, Callanan M, Thieblemont C, Sibon D, Asnafi V, Preudhomme C, Gaulard P, Jardin F, Salles G, Macintyre E.

Hemasphere. 2018 Dec 27;3(1):e169. doi: 10.1097/HS9.0000000000000169. eCollection 2019 Feb.

4.

Clinical outcomes of non-small-cell lung cancer patients with BRAF mutations: results from the French Cooperative Thoracic Intergroup biomarkers France study.

Couraud S, Barlesi F, Fontaine-Deraluelle C, Debieuvre D, Merlio JP, Moreau L, Beau-Faller M, Veillon R, Mosser J, Al Freijat F, Bringuier PP, Léna H, Ouafik L, Westeel V, Morel A, Audigier-Valette C, Missy P, Langlais A, Morin F, Souquet PJ, Planchard D; Biomarkers France Contributors.

Eur J Cancer. 2019 Jul;116:86-97. doi: 10.1016/j.ejca.2019.04.016. Epub 2019 Jun 8.

PMID:
31181537
5.

Mutations of the B-Cell Receptor Pathway Confer Chemoresistance in Primary Cutaneous Diffuse Large B-Cell Lymphoma Leg Type.

Ducharme O, Beylot-Barry M, Pham-Ledard A, Bohers E, Viailly PJ, Bandres T, Faur N, Frison E, Vergier B, Jardin F, Merlio JP, Gros A.

J Invest Dermatol. 2019 Nov;139(11):2334-2342.e8. doi: 10.1016/j.jid.2019.05.008. Epub 2019 May 29.

PMID:
31150604
6.

Primary cutaneous large B-cell lymphomas: relevance of the 2017 World Health Organization classification: clinicopathological and molecular analyses of 64 cases.

Menguy S, Beylot-Barry M, Parrens M, Ledard AP, Frison E, Comoz F, Battistella M, Szablewski V, Balme B, Croue A, Franck F, Ortonne N, Tournier E, Lamant L, Carlotti A, De Muret A, Le Gall F, Lorton MH, Merlio JP, Vergier B.

Histopathology. 2019 Jun;74(7):1067-1080. doi: 10.1111/his.13832. Epub 2019 Apr 25.

PMID:
30715765
7.

Calcium Independent Effect of Orai1 and STIM1 in Non-Hodgkin B Cell Lymphoma Dissemination.

Latour S, Mahouche I, Cherrier F, Azzi-Martin L, Velasco V, Soubeyran P, Merlio JP, Poglio S, Bresson-Bepoldin L.

Cancers (Basel). 2018 Oct 26;10(11). pii: E402. doi: 10.3390/cancers10110402.

8.

A prospective clinical and biological database for pancreatic adenocarcinoma: the BACAP cohort.

Canivet C, Gourgou-Bourgade S, Napoléon B, Palazzo L, Flori N, Guibert P, Piessen G, Farges-Bancel D, Seitz JF, Assenat E, Vendrely V, Truant S, Vanbiervliet G, Berthelémy P, Garcia S, Gomez-Brouchet A, Buscail L, Bournet B; BACAP Consortium.

BMC Cancer. 2018 Oct 16;18(1):986. doi: 10.1186/s12885-018-4906-4.

9.

SATB1 Is a Pivotal Epigenetic Biomarker in Cutaneous T-Cell Lymphomas.

Poglio S, Merlio JP.

J Invest Dermatol. 2018 Aug;138(8):1694-1696. doi: 10.1016/j.jid.2018.04.018.

10.

A Single-Arm Phase II Trial of Lenalidomide in Relapsing or Refractory Primary Cutaneous Large B-Cell Lymphoma, Leg Type.

Beylot-Barry M, Mermin D, Maillard A, Bouabdallah R, Bonnet N, Duval-Modeste AB, Mortier L, Ingen-Housz-Oro S, Ram-Wolff C, Barete S, Dalle S, Maubec E, Quereux G, Templier I, Bagot M, Grange F, Joly P, Vergier B, Vially PJ, Gros A, Pham-Ledard A, Frison E, Merlio JP.

J Invest Dermatol. 2018 Sep;138(9):1982-1989. doi: 10.1016/j.jid.2018.03.1516. Epub 2018 Mar 27.

11.

Double-hit or dual expression of MYC and BCL2 in primary cutaneous large B-cell lymphomas.

Menguy S, Frison E, Prochazkova-Carlotti M, Dalle S, Dereure O, Boulinguez S, Dalac S, Machet L, Ram-Wolff C, Verneuil L, Gros A, Vergier B, Beylot-Barry M, Merlio JP, Pham-Ledard A.

Mod Pathol. 2018 Aug;31(8):1332-1342. doi: 10.1038/s41379-018-0041-7. Epub 2018 Mar 26.

12.

PD-L1 and PD-L2 Are Differentially Expressed by Macrophages or Tumor Cells in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.

Menguy S, Prochazkova-Carlotti M, Beylot-Barry M, Saltel F, Vergier B, Merlio JP, Pham-Ledard A.

Am J Surg Pathol. 2018 Mar;42(3):326-334. doi: 10.1097/PAS.0000000000000983.

PMID:
29112015
13.

Expression of TFH Markers and Detection of RHOA p.G17V and IDH2 p.R172K/S Mutations in Cutaneous Localizations of Angioimmunoblastic T-Cell Lymphomas.

Leclaire Alirkilicarslan A, Dupuy A, Pujals A, Parrens M, Vergier B, Robson A, Delfau-Larue MH, Ingen-Housz-Oro S, Chosidow O, Haioun C, Beylot-Barry M, Merlio JP, Copie-Bergman C, Gaulard P, Ortonne N.

Am J Surg Pathol. 2017 Dec;41(12):1581-1592. doi: 10.1097/PAS.0000000000000956.

PMID:
28945625
14.

Molecular analysis of immunoglobulin variable genes supports a germinal center experienced normal counterpart in primary cutaneous diffuse large B-cell lymphoma, leg-type.

Pham-Ledard A, Prochazkova-Carlotti M, Deveza M, Laforet MP, Beylot-Barry M, Vergier B, Parrens M, Feuillard J, Merlio JP, Gachard N.

J Dermatol Sci. 2017 Nov;88(2):238-246. doi: 10.1016/j.jdermsci.2017.07.008. Epub 2017 Jul 26.

PMID:
28838616
15.

EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice.

Tomasini P, Brosseau S, Mazières J, Merlio JP, Beau-Faller M, Mosser J, Wislez M, Ouafik L, Besse B, Rouquette I, Debieuvre D, Escande F, Westeel V, Audigier-Valette C, Missy P, Langlais A, Morin F, Moro-Sibilot D, Zalcman G, Barlesi F.

Eur Respir J. 2017 Aug 10;50(2). pii: 1700514. doi: 10.1183/13993003.00514-2017. Print 2017 Aug.

16.

Assessment of BRAFV600E mutation in pulmonary Langerhans cell histiocytosis in tissue biopsies and bronchoalveolar lavages by droplet digital polymerase chain reaction.

Pierry C, Caumont C, Blanchard E, Brochet C, Dournes G, Gros A, Bandres T, Verdon S, Marty M, Bégueret H, Merlio JP.

Virchows Arch. 2018 Feb;472(2):247-258. doi: 10.1007/s00428-017-2185-0. Epub 2017 Jul 15.

PMID:
28711990
17.

Identification of Somatic Mutations in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type by Massive Parallel Sequencing.

Mareschal S, Pham-Ledard A, Viailly PJ, Dubois S, Bertrand P, Maingonnat C, Fontanilles M, Bohers E, Ruminy P, Tournier I, Courville P, Lenormand B, Duval AB, Andrieu E, Verneuil L, Vergier B, Tilly H, Joly P, Frebourg T, Beylot-Barry M, Merlio JP, Jardin F.

J Invest Dermatol. 2017 Sep;137(9):1984-1994. doi: 10.1016/j.jid.2017.04.010. Epub 2017 May 4.

18.

TP53 alterations in primary and secondary Sézary syndrome: A diagnostic tool for the assessment of malignancy in patients with erythroderma.

Gros A, Laharanne E, Vergier M, Prochazkova-Carlotti M, Pham-Ledard A, Bandres T, Poglio S, Berhouet S, Vergier B, Vial JP, Chevret E, Beylot-Barry M, Merlio JP.

PLoS One. 2017 Mar 16;12(3):e0173171. doi: 10.1371/journal.pone.0173171. eCollection 2017.

19.

Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France.

Guibert N, Barlesi F, Descourt R, Léna H, Besse B, Beau-Faller M, Mosser J, Pichon E, Merlio JP, Ouafik L, Guichard F, Mastroianni B, Moreau L, Wdowik A, Sabourin JC, Lemoine A, Missy P, Langlais A, Moro-Sibilot D, Mazières J.

J Thorac Oncol. 2017 Jun;12(6):963-973. doi: 10.1016/j.jtho.2017.02.001. Epub 2017 Feb 9.

20.

Evaluation of a fast and fully automated platform to diagnose EGFR and KRAS mutations in formalin-fixed and paraffin-embedded non-small cell lung cancer samples in less than one day.

Lambros L, Caumont C, Guibourg B, Barel F, Quintin-Roué I, Marcorelles P, Merlio JP, Uguen A.

J Clin Pathol. 2017 Jun;70(6):544-549. doi: 10.1136/jclinpath-2016-204202. Epub 2017 Feb 2.

PMID:
28153953

Supplemental Content

Loading ...
Support Center